Our Mission

Immunyx is pioneering new approaches to immune modulation using targeted nanoparticles to change the function of neutrophils. Our team of world experts in neutrophil biology and nanoparticle development are using cutting edge tools to bring new therapies to patients across a broad spectrum of diseases. The company was founded based on technology from the Hebrew University with the backing of VLX Ventures.


Seth Salpeter, Ph.D
Co-Founder & CEO

Dr. Salpeter has deep experience in developing and bringing new biotechnologies to market. He previously served as Co-Founder and CTO at Curesponse, a precision cancer medicine company. Prior to that he was Chief Scientist and VP Business Development at Sight Diagnostics. Dr. Salpeter holds a Ph.D in Biochemistry from the Hebrew University and performed post-doctoral studies at the Institute for Drug Research, the Hebrew University School of Pharmacy


Zvika Granot, Ph.D
Co-Founder & CSO

Dr. Granot is a Professor at the Hebrew University School of Medicine. After receiving his Ph.D at the Hebrew University, he performed post-doctoral work at Memorial Sloan Kettering where he focused on the role of neutrophil biology in cancer. Since launching his laboratory he has continued to research the neutrophil’s role in disease, recently discovering the high and low density paradigm of neutrophil regulation.

Zvi Fridlender, M.D, Ms.C
Co-Founder & CMO

Dr. Fridlender is a Professor at the Hebrew University Medical School Hadassah Hospital where he is director of the Lung COPD unit and head of the Lung Cancer laboratory. Dr. Fridlender performed post-doctoral work at the University of Pennsylvania where he discovered the N1 & N2 neutrophil phenotypes in cancer. In his own laboratory, he continues to focus on the role of neutrophils in cancer and their interaction with the microenvironment.

Scientific Advisory Board

Dr. Daryl Drummond, Ph.D

Chief Scientific Officer at Akagera Medicines, Inc and Interim Head of R&D – Tidal Therapeutics

International expert in targeted therapies. 

Prof. Chezy Barenholz
Professor Hebrew University

Inventor of Doxil, international expert in liposomes

Ronit Satchi-Fainaro, Ph.D
Professor of Pharmacology – Tel Aviv University; Head – Cancer Research and Nanomedicine Lab

Expert in nano-particle delivery and preclinical systems. 

Bartolome R. Celli, MD
Physician, Brigham and Women’s Hospital Professor of Medicine, Harvard Medical School
Leading expert in COPD. Former director of COPD & Pulmonology at Mass General Hospital